Potency of VEGFR inhibitors in kidney cancer could translate into greater efficacy
This article was originally published in Scrip
Executive Summary
Pfizer's new, investigational, anti-angiogenic VEGF receptor inhibitor, axitinib, has improved progression-free survival (PFS) compared with Bayer/Onyx's Nexavar (sorafenib) in its first Phase III trial, AXIS, in metastatic renal cell carcinoma (RCC), which was in the second-line setting.